J&J Hit With Untitled Letter for Misleading Xarelto Ad

The FDA flagged a direct-to-consumer advertisement for Johnson & Johnson’s (J&J) blood-thinner Xarelto as misleading, handing the drugmaker a second untitled letter in as many months. The latest letter to J&J from the agency’s Office of Prescription Drug Promotion, posted June 19, relates to a print ad the FDA says minimizes the drug’s risks and makes a misleading claim.
Washington Drug Letter